We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Nkarta Inc is a biopharmaceutical company developing engineered natural killer (NK) cells to fight cancer. The company is focused on leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and d... Nkarta Inc is a biopharmaceutical company developing engineered natural killer (NK) cells to fight cancer. The company is focused on leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. It is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of tumor targets, and improve persistence for sustained activity in the body for the treatment of cancer. The company's operations are based in South San Francisco, California and it operates in one segment. Show more
Patient screening underway in Ntrust-1, the first U.S.-based clinical trial of an engineered NK cell therapy for the treatment of lupus nephritis IND cleared for Ntrust-2, a clinical trial for...
SOUTH SAN FRANCISCO, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies...
Dosing of first patient with NKX019 for lupus nephritis using disease-tailored lymphodepletion expected in first half of 2024Cash balance of $450.0 million on March 31, 2024, including cash, cash...
Period β | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.57 | 10.6741573034 | 5.34 | 6.15 | 5.05 | 1023397 | 5.79093656 | CS |
4 | -0.65 | -9.90853658537 | 6.56 | 7.3899 | 5.04 | 687981 | 6.04044518 | CS |
12 | -3.47 | -36.9936034115 | 9.38 | 9.7 | 5.04 | 791528 | 6.95062363 | CS |
26 | 0.48 | 8.83977900552 | 5.43 | 16.24 | 5.04 | 1488455 | 9.33359984 | CS |
52 | 3.08 | 108.833922261 | 2.83 | 16.24 | 1.28 | 1550753 | 5.90675557 | CS |
156 | -23.97 | -80.2208835341 | 29.88 | 40.64 | 1.28 | 1016656 | 10.27730681 | CS |
260 | -48.84 | -89.2054794521 | 54.75 | 79.16 | 1.28 | 821470 | 12.20059327 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions